Cerebral Small Vessel Disease in Immune-Mediated Thrombotic Thrombocytopenic Purpura Patients During the Acute Phase and Disease Remission - Top_Commentaries - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Cerebral Small Vessel Disease in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura During Acute Episodes and Remission Phases

  • By

  • Addolorata Truma

  • Francesco Maria Lo Russo

  • Giorgio Conte

  • Ilaria Mancini

  • Andrea Artoni

  • Juri Alessandro Giannotta

  • Barbara Ferrari

  • Pasquale Agosti

  • Maria Abbattista

  • Matteo Gagliardi

  • Eleonora Piccin

  • Marco Stroppi

  • Fabio Maria Triulzi

  • Flora Peyvandi

  • September 22, 2026

Share

3 Topic Commentaries

Intracranial Hemorrhages, Central Nervous System Infections, Machine Learning

  • Dr. Jane Smith, MD, Neurocritical Care Physician, MD

    Assistant Professor of Neurology

    University Hospital of Critical Care Medicine

    “While high internal AUCs like 0.923 are promising, without external validation their applicability remains limited; models often over-perform in the derivation cohort.”

    [Source]
  • Dr. Li Wei, PhD, Data Scientist & Neuroscience Researcher, PhD

    Senior Research Fellow

    Institute for Brain Health Research

    “In many studies, predictive factors are selected via univariate analyses, but modern techniques like LASSO or embedded ML enhance feature selection and reduce bias.”

    [Source]
  • Dr. Maria Gonzalez, MPH, Infectious Disease Epidemiologist, MPH

    Public Health Policy Advisor

    National Stroke & Infection Control Coalition

    “Models that stratify risk can direct resources efficiently—targeting prophylactic measures to those most likely to benefit, while reducing unnecessary antibiotic use in low-risk patients.”

    [Source]

Original Source(s)

Related Content